Novavax Is Maintained at Buy by B. Riley Securities

Novavax Is Maintained at Buy by B. Riley Securities

Dow JonesMay 23 09:37 ET

B.Riley Financial Maintains Novavax(NVAX.US) With Buy Rating, Raises Target Price to $29

B.Riley Financial analyst Mayank Mamtani maintains $Novavax(NVAX.US)$ with a buy rating, and adjusts the target price from $11 to $29.According to TipRanks data, the analyst has a success rate of 26.1

moomoo NewsMay 23 08:33 ET

Moderna, CureVac, Other Vaccine Stocks Jump as New Human Bird-flu Cases Reported in U.S., Australia

Vaccine-related stocks moved sharply higher Wednesday as new human bird-flu cases were reported in the U.S. and Australia.

MarketWatchMay 22 22:30 ET

Novavax Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/23/2024 77.7% B. Riley Securities $11 → $29 Maintains Buy 05/13/2024 -38.73% TD Cowen $5 → $10 Maintain

BenzingaMay 23 09:26 ET

Express News | Novavax Shares up 4.7% Premarket After B. Riley Raises PT on Co's Shares to $29 From $11

ReutersMay 23 08:41 ET

Express News | Novavax Inc : B. Riley Raises Target Price to $29 From $11

ReutersMay 23 06:35 ET